Europese Unie - Portugees - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem de sódio - infecções bacterianas - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 e 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. deve ser tido em consideração a orientação oficial sobre o uso apropriado de agentes antibacterianos..

Europese Unie - Portugees - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatida - osteoporosis; osteoporosis, postmenopausal - homeostase de cálcio - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Europese Unie - Portugees - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triplo terapia de combinação), como adjuvante da dieta e exercício em pacientes inadequadamente controlados em sua máxima tolerada, a dose de metformina e uma sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europese Unie - Portugees - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Portugal - Portugees - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

farmoz - sociedade técnico medicinal, s.a. - sunitinib - cápsula - 12.5 mg - sunitinib malato 16.7063 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - Portugees - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

farmoz - sociedade técnico medicinal, s.a. - sunitinib - cápsula - 50 mg - sunitinib malato 66.825 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - Portugees - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

farmoz - sociedade técnico medicinal, s.a. - sunitinib - cápsula - 25 mg - sunitinib malato 33.4126 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - Portugees - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

farmoz - sociedade técnico medicinal, s.a. - sunitinib - cápsula - 25 mg - sunitinib malato 33.4126 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - Portugees - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

farmoz - sociedade técnico medicinal, s.a. - sunitinib - cápsula - 37.5 mg - sunitinib malato 50.1189 mg - sunitinib - genérico - duração do tratamento: longa duração

Portugal - Portugees - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

farmoz - sociedade técnico medicinal, s.a. - sunitinib - cápsula - 50 mg - sunitinib malato 66.825 mg - sunitinib - genérico - duração do tratamento: longa duração